{"product_id":"freund-pestle-analysis","title":"Freund PESTLE Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Competitive Advantage Starts with This Report\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how political shifts, economic trends, and technological disruption are reshaping Freund’s competitive landscape with our concise PESTLE snapshot—then unlock the full analysis for deep, actionable insights. Purchase the complete PESTLE to access expert research, editable charts, and strategic recommendations tailored for investors, consultants, and managers. Get instant clarity and make smarter decisions—download now.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eolitical factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeopolitical Trade Dynamics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs a Japanese manufacturer of specialized pharmaceutical machinery, Freund faces shifting trade relations with the US and China that affected 2024–25 export flows—Japan’s pharma equipment exports to the US rose 7% in 2024 while shipments to China fell 5%. Heightened scrutiny of high-tech exports has prompted tighter licensing; METI implemented expanded controls in 2025 covering precision manufacturing tools relevant to drug production. By 2026 Freund must adapt compliance costs and dual‑sourcing to protect supply‑chain integrity and sustain global market share.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGovernment Healthcare Subsidies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpmany governments boosted pharmaceutical production subsidies after covid-19 disruptions for example india increased incentives to in and the us chips-like manufacturing directed biopharma initiatives driving a yoy rise capital equipment orders asia freund as supplier of granulation coating systems is positioned capture share domestic drugmakers modernize facilities north american capex pharma rose underpinning sustained demand. continued political emphasis on medicine self-sufficiency across america remains primary demand driver machinery sales service contracts.\u003e\n\u003c\/pmany\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDrug Pricing Regulations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical pressure to lower healthcare spending drives government-mandated drug price cuts, notably Japan’s 2024 National Health Insurance reductions averaging 7.5% for selected molecules, squeezing pharma margins. Such cuts prompt drugmakers to delay or shrink capex, reducing demand for Freund’s filling and packaging equipment. Freund must quantify equipment ROI—e.g., 15–25% throughput gains and 10–20% unit-cost reduction—to justify purchases under tighter budgets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Harmonization Initiatives\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePolitical efforts like ICH revisions influence Freund’s machine design and CE\/ISO certification; ICH updated guidelines in 2024 affecting pharma equipment validation across EU, US and JP markets.\u003c\/p\u003e\n\u003cp\u003eAs blocs harmonize standards, Freund must meet top-tier requirements to avoid losing access to markets representing \u0026gt;60% of global pharma sales (2024 est. $1.4tn).\u003c\/p\u003e\n\u003cp\u003eHarmonization eases entry into emerging markets but demands ongoing monitoring of policy shifts and compliance costs, which can add 1–3% to capex.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eICH 2024 guideline updates impact validation\/specs\u003c\/li\u003e\n\u003cli\u003eTarget markets represent \u0026gt;60% of $1.4tn pharma sales (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance monitoring can raise capex 1–3%\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCorporate Tax and Incentive Policies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eJapanese tax credits for R\u0026amp;D—up to 25% for certain SMEs and enhanced deductions (up to 30% in some programs)—directly boost Freund’s margins by lowering effective tax on AI and machinery R\u0026amp;D spend; in FY2024 Japan’s R\u0026amp;D tax support expanded ~10% vs 2023, benefiting capital-intensive firms.\u003c\/p\u003e\n\u003cp\u003eTargeted incentives for digital transformation and green manufacturing (e.g., subsidies covering up to 50% of CAPEX for energy-efficiency upgrades) push Freund toward AI-driven automation and low-emission systems, lowering payback periods on new equipment.\u003c\/p\u003e\n\u003cp\u003ePlanned fiscal reviews through end-2025 create execution risk: a rollback of enhanced R\u0026amp;D credits or green CAPEX subsidies could delay Freund’s planned ¥2–3 billion tech investments, altering ROI timelines.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eR\u0026amp;D tax credits: up to 25–30%\u003c\/li\u003e\n\u003cli\u003eGreen\/digital CAPEX subsidies: up to 50%\u003c\/li\u003e\n\u003cli\u003eFY2024 R\u0026amp;D support +10% vs 2023\u003c\/li\u003e\n\u003cli\u003ePlanned Freund tech spend at risk: ¥2–3 billion if policies change\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTrade shifts, policy risks squeeze pharma margins as capex, credits and subsidies rise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eTrade shifts (US exports +7% to 2024; China -5%), METI 2025 export controls, govt pharma capex up (Asia orders +12% 2024; North America capex +9% 2024), Japan drug-price cuts -7.5% (2024) pressure margins, ICH 2024 guideline updates, R\u0026amp;D tax credits 25–30%, green CAPEX subsidies up to 50%; policy rollbacks could threaten Freund’s ¥2–3bn tech spend.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS export change\u003c\/td\u003e\n\u003ctd\u003e+7% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChina export change\u003c\/td\u003e\n\u003ctd\u003e-5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsia orders\u003c\/td\u003e\n\u003ctd\u003e+12% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNA capex\u003c\/td\u003e\n\u003ctd\u003e+9% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan price cuts\u003c\/td\u003e\n\u003ctd\u003e-7.5% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D credit\u003c\/td\u003e\n\u003ctd\u003e25–30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGreen subsidies\u003c\/td\u003e\n\u003ctd\u003eup to 50%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAt-risk spend\u003c\/td\u003e\n\u003ctd\u003e¥2–3bn\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eExplores how external macro-environmental factors uniquely affect the Freund across six dimensions—Political, Economic, Social, Technological, Environmental, and Legal—backed by current data and trends to identify threats and opportunities for executives, consultants, and entrepreneurs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eFreund PESTLE Analysis condenses complex macro-environment insights into a clean, easily shareable summary—visually segmented by PESTLE categories and written in plain language to speed meeting prep, support risk discussions, and slot directly into presentations or client reports.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eE\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003economic factors\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCurrency Exchange Rate Volatility\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eFreund’s earnings are highly sensitive to JPY\/USD and JPY\/EUR moves: in 2025 exports made up 62% of revenue, so a 10% yen depreciation lifted export competitiveness but raised imported-raw-material costs by ~4.5% of COGS. The firm reported hedging coverage of 68% of FX exposure at end-2025, and analysts in 2026 keep FX risk management as a key valuation driver.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Interest Rate Environment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Bank of Japan's 2024 shift from negative rates toward a 0.1–0.5% range raises borrowing costs for Freund's capital-intensive projects, with global policy rates averaging ~3.5% in 2025; higher rates can cut clients' purchasing power—OECD household credit growth slowed to 2.1% YoY in 2024—leading to delayed equipment orders due to pricier financing. Monitoring Freund's weighted average cost of capital, which could rise 100–200 bps, is essential for long-term investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInflationary Pressure on Raw Materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRising costs for specialized metals, electronic components and chemical inputs for excipients increased Freund’s input costs by an estimated 8–12% in 2024, squeezing gross margins on coating and granulation systems; while about 60% of cost rises can be passed to customers, abrupt inflation spikes require agile pricing—average lead-time hedging and supplier diversification cut exposure by ~25% in 2023–24. Managing these inputs is critical to keep competitive pricing.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEmerging Market Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eEconomic expansion in Southeast Asia and India—projected GDP growth of 4.5–6% annually through 2025–26—boosts demand for generics, creating a larger market for Freund’s powder-processing equipment and excipients; India’s pharma exports reached about $25.6B in 2024, with generics rising.\u003c\/p\u003e\n\u003cp\u003eTo capture this, Freund needs localized sales strategies and technical-support hubs; establishing regional service centers can reduce downtime and support OEMs scaling production.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSE Asia\/India GDP growth 4.5–6% (2025 est)\u003c\/li\u003e\n\u003cli\u003eIndia pharma exports ~$25.6B (2024)\u003c\/li\u003e\n\u003cli\u003eSurge in generics = higher demand for powder tech\u003c\/li\u003e\n\u003cli\u003eLocal sales + regional service centers critical\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLabor Market Constraints\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eJapan’s labor force fell 0.5% in 2024 to 66.7m and engineering shortages are global; Freund faces rising labor costs—wages in Japanese manufacturing rose 3.1% y\/y in 2024—driving recruitment challenges for specialized engineers.\u003c\/p\u003e\n\u003cp\u003eTo stay competitive Freund must invest in automation (robot density in Japan ~390 robots per 10,000 workers in 2023) and raise wages to attract talent, while prioritizing productivity gains and multi-year human capital development programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eShrinking workforce: Japan labor force 66.7m (2024)\u003c\/li\u003e\n\u003cli\u003eWage pressure: manufacturing wages +3.1% (2024)\u003c\/li\u003e\n\u003cli\u003eAutomation benchmark: 390 robots\/10,000 workers (2023)\u003c\/li\u003e\n\u003cli\u003eAction: invest in automation, higher wages, long-term training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Box-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFreund: FX, rising WACC and input inflation squeeze margins despite export tailwinds\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eFreund’s 2024–25 revenue mix (62% exports) makes earnings highly FX-sensitive; 68% hedged at end-2025 but a 10% JPY depreciation raised imported COGS ~4.5%. Higher rates (BOJ 0.1–0.5% in 2024; global ~3.5% in 2025) may lift WACC 100–200bps, slowing capex demand. Input inflation (specialty metals\/components +8–12% in 2024) squeezed margins; SE Asia\/India GDP 4.5–6% and India pharma exports ~$25.6B (2024) drive demand; Japan labor force 66.7m and wages +3.1% (2024) pressure costs.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eExport share (2025)\u003c\/td\u003e\n\u003ctd\u003e62%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFX hedged (end-2025)\u003c\/td\u003e\n\u003ctd\u003e68%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJPY depreciation effect on COGS\u003c\/td\u003e\n\u003ctd\u003e~4.5% per 10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWACC up\u003c\/td\u003e\n\u003ctd\u003e+100–200bps (est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInput cost rise (2024)\u003c\/td\u003e\n\u003ctd\u003e8–12%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSE Asia\/India GDP (2025 est)\u003c\/td\u003e\n\u003ctd\u003e4.5–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eIndia pharma exports (2024)\u003c\/td\u003e\n\u003ctd\u003e$25.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan labor force (2024)\u003c\/td\u003e\n\u003ctd\u003e66.7m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eJapan manufacturing wages (2024)\u003c\/td\u003e\n\u003ctd\u003e+3.1% YoY\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eFreund PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact Freund PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56751493480825,"sku":"freund-pestle-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/freund-pestle-analysis.png?v=1772232164","url":"https:\/\/matrixbcg.com\/products\/freund-pestle-analysis","provider":"MatrixBCG","version":"1.0","type":"link"}